PMID- 32992413
OWN - NLM
STAT- MEDLINE
DCOM- 20201005
LR  - 20220531
IS  - 0529-5807 (Print)
IS  - 0529-5807 (Linking)
VI  - 49
IP  - 10
DP  - 2020 Oct 8
TI  - [Clinicopathological study of large B-cell lymphoma with IRF4 rearrangement].
PG  - 1003-1008
LID - 10.3760/cma.j.cn112151-20200601-00433 [doi]
AB  - Objective: To study the clinicopathological features of large B-cell lymphoma 
      (LBCL) with IRF4 rearrangement. Methods: Seven cases of LBCL with IRF4 
      rearrangement collected at the First Affiliated Hospital of Nanjing Medical 
      University from November 2018 to October 2019 were evaluated by hematoxylin and 
      eosin staining, immunohistochemistry and fluorescence in situ hybridization 
      detection. The relevant literature was reviewed. Results: Four tumors were 
      located in the tonsils, 2 tumors in the lymphoid nodes and one tumor in the 
      adenoid.The patients were 3 males and 4 females patients with a median age of 24 
      years (range, 6 to 39 years).Microscopically, entirely follicular pattern was 
      present in one case, entirely diffuse pattern in 2 cases, and follicular and 
      diffuse pattern in other 4 cases. The tumor cells were medium to large in size 
      and showed the morphology of centroblasts or blastoid cells with irregular 
      nuclei, brisk mitotic activity in 3 cases and starry sky in 2 cases. All of the 
      cases were positive for CD20, PAX-5, bcl-6, and MUM1 and had a Ki-67 index>80%, 
      while CD10 and bcl-2 were positive in 3 cases. IRF4 gene rearrangement was 
      identified in all cases and bcl-6 gene rearrangement in 2 cases. All patients 
      presented with localized disease with clinical stage Ⅰ or Ⅱ, except one with 
      stage Ⅳ at presentation and a new lesion in the mediastinum developed 8 months 
      later. Conclusions: LBCL with IRF4 rearrangement is a clinicopathologically 
      distinct entity. The observations reveal a broader spectrum of morphology and 
      biological behaviors. The relationship between clinical stage and prognosis needs 
      to be determined in more cases.
FAU - Chen, W
AU  - Chen W
AD  - Department of Pathology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Gong, Q X
AU  - Gong QX
AD  - Department of Pathology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Li, X
AU  - Li X
AD  - Department of Pathology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Song, G X
AU  - Song GX
AD  - Department of Pathology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Wang, Z
AU  - Wang Z
AD  - Department of Pathology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Xu, W
AU  - Xu W
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
FAU - Zhang, Z H
AU  - Zhang ZH
AD  - Department of Pathology, the First Affiliated Hospital of Nanjing Medical 
      University, Nanjing 210029, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Bing Li Xue Za Zhi
JT  - Zhonghua bing li xue za zhi = Chinese journal of pathology
JID - 0005331
RN  - 0 (Interferon Regulatory Factors)
RN  - 0 (interferon regulatory factor-4)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Interferon Regulatory Factors/genetics
MH  - *Lymphoma, B-Cell
MH  - *Lymphoma, Follicular
MH  - *Lymphoma, Non-Hodgkin
MH  - Male
MH  - Young Adult
OTO - NOTNLM
OT  - Immunohistochemistry
OT  - Lymphoma, B-cell
OT  - Pathology, molecular
EDAT- 2020/09/30 06:00
MHDA- 2020/10/06 06:00
CRDT- 2020/09/29 22:50
PHST- 2020/09/29 22:50 [entrez]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2020/10/06 06:00 [medline]
AID - 10.3760/cma.j.cn112151-20200601-00433 [doi]
PST - ppublish
SO  - Zhonghua Bing Li Xue Za Zhi. 2020 Oct 8;49(10):1003-1008. doi: 
      10.3760/cma.j.cn112151-20200601-00433.